Cancer drug combo trial for rare blood cancers pulled before starting
NCT ID NCT06284460
First seen Feb 14, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study was designed to test a combination of two drugs (ASTX727 and ASTX029) in adults with certain genetic mutations (RAS pathway) in myelodysplastic syndromes or related blood cancers. The goal was to find a safe dose and see if it could control the disease. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Cente
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.